Combined effect of genetic polymorphisms in phase i and II biotransformation enzymes on head and neck cancer risk

Head and Neck

Volumn 35, Issue 6, 2013, Pages 858-867

  Lacko, Martin ^a   Voogd, Adri C ^b   Roelofs, Hennie M J ^c   Te Morsche, Rene H M ^c   Ophuis, Michel B Oude ^a,d   Peters, Wilbert H M ^c   Manni, Johannes J ^a  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b MAASTRICHT UNIVERSITY   (Netherlands)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^d VIECURI MEDICAL CENTER   (Netherlands)

Author keywords

carcinogenesis; genetic susceptibility; head and neck neoplasm; smoking; UGT1A1

Indexed keywords

ALCOHOL; GLUCURONOSYLTRANSFERASE 1A1; GLUCURONOSYLTRANSFERASE 1A6; GLUCURONOSYLTRANSFERASE 1A7; GLUCURONOSYLTRANSFERASE 1A8; GLUCURONOSYLTRANSFERASE 2B17; GLUCURONOSYLTRANSFERASE 2B4; GLUCURONOSYLTRANSFERASE 2B7; GLYCOSYLTRANSFERASE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BIOTRANSFORMATION; CANCER PATIENT; CANCER RISK; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; GENETIC POLYMORPHISM; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SMOKING;

ADULT; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; CYCLOOXYGENASE 2; EPOXIDE HYDROLASES; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; GLUCURONOSYLTRANSFERASE; HEAD AND NECK NEOPLASMS; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; SMOKING; YOUNG ADULT;

EID: 84878011303     PISSN: 10433074     EISSN: 10970347     Source Type: Journal    
DOI: 10.1002/hed.23054     Document Type: Article

References (44)

1. Maier H, Dietz A, Gewelke U, Heller WD, Weidauer H,. Tobacco and alcohol and the risk of head and neck cancer. Clin Investig 1992; 70: 320-327.
2. Raitiola HS, Pukander JS,. Etiological factors of laryngeal cancer. Acta Otolaryngol Suppl 1997; 529: 215-217.
3. Riedel F, Goessler U, Hörmann K,. Alcohol-related diseases of the mouth and throat. Best Pract Res Clin Gastroenterol 2003; 17: 543-555.
4. Vidal L, Gillison ML,. Human papillomavirus in HNSCC: recognition of a distinct disease type. Hematol Oncol Clin North Am 2008; 22: 1125-1142.
5. Wogan GN, Hecht SS, Felton JS, Conney AH, Loeb LA,. Environmental and chemical carcinogenesis. Semin Cancer Biol 2004; 14: 473-486.
6. Califano J, van der Riet P, Westra W, et al. Genetic progression model for head and neck cancer: implications for field cancerization. Cancer Res 1996; 56: 2488-2492.
7. Forastiere A, Koch W, Trotti A, Sidransky D,. Head and neck cancer. N Engl J Med 2001; 345: 1890-1900.
8. Hecht SS,. Tobacco carcinogens, their biomarkers and tobacco-induced cancer. Nat Rev Cancer 2003; 3: 733-744.
9. Hecht SS,. Progress and challenges in selected areas of tobacco carcinogenesis. Chem Res Toxicol 2008; 21: 160-171.
10. Shimada T,. Xenobiotic-metabolizing enzymes involved in activation and detoxification of carcinogenic polycyclic aromatic hydrocarbons. Drug Metab Pharmacokinet 2006; 21: 257-276.
11. Nebert DW, Dalton TP,. The role of cytochrome P450 enzymes in endogenous signalling pathways and environmental carcinogenesis. Nat Rev Cancer 2006; 6: 947-960.
12. Jiang H, Gelhaus SL, Mangal D, Harvey RG, Blair IA, Penning TM,. Metabolism of benzo[a]pyrene in human bronchoalveolar H358 cells using liquid chromatography-mass spectrometry. Chem Res Toxicol 2007; 20: 1331-1341.
13. Romano M, Claria J,. Cyclooxygenase-2 and 5-lipoxygenase converging functions on cell proliferation and tumor angiogenesis: implications for cancer therapy. FASEB J 2003; 17: 1986-1995.
14. Murata H, Kawano S, Tsuji S, et al. Cyclooxygenase-2 overexpression enhances lymphatic invasion and metastasis in human gastric carcinoma. Am J Gastroenterol 1999; 94: 451-455.
15. Lacko M, Roelofs HM, Te Morsche RH, et al. Microsomal epoxide hydrolase genotypes and the risk for head and neck cancer. Head Neck 2008; 30: 836-844.
16. Peters WH, Lacko M, Te Morsche RH, Voogd AC, Oude Ophuis MB, Manni JJ,. COX-2 polymorphisms and the risk for head and neck cancer in white patients. Head Neck 2009; 31: 938-943.
17. Tukey RH, Strassburg CP,. Human UDP-glucuronosyltransferases: metabolism, expression, and disease. Annu Rev Pharmacol Toxicol 2000; 40: 581-616.
18. Zheng Z, Fang JL, Lazarus P,. Glucuronidation: an important mechanism for detoxification of benzo[a]pyrene metabolites in aerodigestive tract tissues. Drug Metab Dispos 2002; 30: 397-403.
19. Ohno S, Nakajin S,. Determination of mRNA expression of human UDP-glucuronosyltransferases and application for localization in various human tissues by real-time reverse transcriptase-polymerase chain reaction. Drug Metab Dispos 2009; 37: 32-40.
20. Lacko M, Roelofs HM, Te Morsche RH, et al. Genetic polymorphism in the conjugating enzyme UGT1A1 and the risk of head and neck cancer. Int J Cancer 2010; 127: 2815-2821.
21. Benhamou S, Reinikainen M, Bouchardy C, Dayer P, Hirvonen A,. Association between lung cancer and microsomal epoxide hydrolase genotypes. Cancer Res 1998; 58: 5291-5293.
22. Zhang X, Miao X, Tan W, et al. Identification of functional genetic variants in cyclooxygenase-2 and their association with risk of esophageal cancer. Gastroenterology 2005; 129: 565-576.
23. Papafili A, Hill MR, Brull DJ, et al. Common promoter variant in cyclooxygenase-2 represses gene expression: evidence of role in acute-phase inflammatory response. Arterioscler Thromb Vasc Biol 2002; 22: 1631-1636.
24. Raijmakers MT, Jansen PL, Steegers EA, Peters WH,. Association of human liver bilirubin UDP-glucuronyltransferase activity with a polymorphism in the promoter region of the UGT1A1 gene. J Hepatol 2000; 33: 348-351.
25. Nagar S, Remmel RP,. Uridine diphosphoglucuronosyltransferase pharmacogenetics and cancer. Oncogene 2006; 25: 1659-1672.
26. Butler LM, Duguay Y, Millikan RC, et al. Joint effects between UDP-glucuronosyltransferase 1A7 genotype and dietary carcinogen exposure on risk of colon cancer. Cancer Epidemiol Biomarkers Prev 2005; 14: 1626-1632.
27. Huang YH, Galijatovic A, Nguyen N, et al. Identification and functional characterization of UDP-glucuronosyltransferases UGT1A8*1, UGT1A8*2 and UGT1A8*3. Pharmacogenetics 2002; 12: 287-297.
28. Ginsberg G, Guyton K, Johns D, Schimek J, Angle K, Sonawane B,. Genetic polymorphism in metabolism and host defense enzymes: implications for human health risk assessment. Crit Rev Toxicol 2010; 40: 575-619.
29. Lazarus P, Zheng Y, Aaron Runkle E, Muscat JE, Wiener D,. Genotype-phenotype correlation between the polymorphic UGT2B17 gene deletion and NNAL glucuronidation activities in human liver microsomes. Pharmacogenet Genomics 2005; 15: 769-778.
30. Benhamou S, Benhamou E, Flamant R,. Lung cancer risk associated with cigar and pipe smoking. Int J Cancer 1986; 37: 825-829.
31. Elahi A, Bendaly J, Zheng Z, et al. Detection of UGT1A10 polymorphisms and their association with orolaryngeal carcinoma risk. Cancer 2003; 98: 872-880.
32. Lampe JW, Bigler J, Horner NK, Potter JD,. UDP-glucuronosyltransferase (UGT1A1*28 and UGT1A6*2) polymorphisms in Caucasians and Asians: relationships to serum bilirubin concentrations. Pharmacogenetics 1999; 9: 341-349.
33. Lacko M, Roelofs HM, te Morsche RH, et al. Genetic polymorphisms in the tobacco smoke carcinogens detoxifying enzyme UGT1A7 and the risk of head and neck cancer. Head Neck 2009; 31: 1274-1281.
34. Berkhout M, Roelofs HM, te Morsche RH, et al. Detoxification enzyme polymorphisms are not involved in duodenal adenomatosis in familial adenomatous polyposis. Br J Surg 2008; 95: 499-505.
35. van der Logt EM, te Morsche RH, Groenendaal N, et al. Genetic polymorphism in UDP-glucuronosyltransferase 2B7 and colorectal cancer risk. Oncol Res 2009; 17: 323-329.
36. Wilson W, III, Pardo-Manuel de Villena F, Lyn-Cook BD, et al. Characterization of a common deletion polymorphism of the UGT2B17 gene linked to UGT2B15. Genomics 2004; 84: 707-714.
37. McCarty MF,. "Iatrogenic Gilbert syndrome"-a strategy for reducing vascular and cancer risk by increasing plasma unconjugated bilirubin. Med Hypotheses 2007; 69: 974-994.
38. Zucker SD, Horn PS, Sherman KE,. Serum bilirubin levels in the U.S. population: gender effect and inverse correlation with colorectal cancer. Hepatology 2004; 40: 827-835.
39. Keshavan P, Schwemberger SJ, Smith DL, Babcock GF, Zucker SD,. Unconjugated bilirubin induces apoptosis in colon cancer cells by triggering mitochondrial depolarization. Int J Cancer 2004; 112: 433-445.
40. Lin JP, Vitek L, Schwertner HA,. Serum bilirubin and genes controlling bilirubin concentrations as biomarkers for cardiovascular disease. Clin Chem 2010; 56: 1535-1543.
41. Schwertner HA, Vitek L,. Gilbert syndrome, UGT1A1*28 allele, and cardiovascular disease risk: possible protective effects and therapeutic applications of bilirubin. Atherosclerosis 2008; 198: 1-11.
42. Vitek L, Schwertner HA,. Protective effects of serum bilirubin on peripheral vascular disease. Ann Hepatol 2008; 7: 94-95.
43. Lin JP, Schwaiger JP, Cupples LA, et al. Conditional linkage and genome-wide association studies identify UGT1A1 as a major gene for anti-atherogenic serum bilirubin levels-the Framingham Heart Study. Atherosclerosis 2009; 206: 228-233.
44. Köhle C, Möhrle B, Münzel PA, et al. Frequent co-occurrence of the TATA box mutation associated with Gilbert's syndrome (UGT1A1*28) with other polymorphisms of the UDP-glucuronosyltransferase-1 locus (UGT1A6*2 and UGT1A7*3) in Caucasians and Egyptians. Biochem Pharmacol 2003; 65: 1521-1527.